Join panelists Donna Ryan, MD, Ethan Lazarus, MD, and Lawrence Herman, DMSc PA-C, as they address frequently asked questions about the use of glucagon- like peptide-1 receptor agonist (GLP-1 RA) in appropriate adults with obesity or overweight and at least one weight-related comorbidity.
Join panelists Donna Ryan, MD, Professor Emerita at the Pennington Biomedical Research Center in Baton Rouge, Louisiana, Ethan Lazarus, MD, Director of Clinical Nutrition Center in Denver, Colorado, and Lawrence Herman, DMSc PA-C, Adjunct Professor at the University of Lynchburg and President of Palantir Healthcare, LLC, in Greenville, South Carolina, as they address frequently asked questions about the use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) in appropriate adults with obesity or overweight and at least one weight-related comorbidity. The discussion includes commonly asked questions about trial design from relevant chronic weight- management and cardiovascular outcomes trials, efficacy and safety data, and practical guidance on dosing and administration.
Please see Prescribing Information, including boxed warning.
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
The moderator and expert discussants were compensated by Novo Nordisk for their participation in this podcast.
Faculty Presenters:
Donna Ryan, MD
Professor Emerita
Pennington Biomedical Research Center
Baton Rouge, LA
Ethan Lazarus, MD, MFOMA
Clinical Nutrition Center
Anschutz Medical Center
Denver, CO
Lawrence Herman, DMSc, MPA, PA-C
Palantir Healthcare, LLC
Boiling Springs, South Carolina
Doctor of Medical Science Program, University of Lynchburg
Lynchburg, Virginia